Regeneron registers prostate cancer bispecific trial; posts REGN5381 heart failure resultsSep 30Weekly roundup, 4 itemsamrecibartcenvacibartUpdated
Regeneron registers Phase 3 cat allergy trial and Phase 1/2 glaucoma antibody studyJun 30Weekly roundup, 2 itemsfreneslerbartmevonlerbart
Sign inSign in